Why carry out this study?

To date, there are no clear guidelines for steroid therapy in myasthenia gravis in terms of starting, tapering, and chronic management.

An Expert Opinion methodology has been used to discuss clinical relevant issues about the use of corticosteroids in myasthenia gravis.

What was learned from this study?

Starting therapy with corticosteroids may temporarily exacerbate the symptoms of myasthenia gravis, leading to severe consequences and chronic steroid therapy carries a burden in terms of indirect costs due to side effects in myasthenia gravis.

Non-steroidal immunosuppressant agents have allow to reduce steroid intake with relevant side effects.

In the era of the new therapies for myasthenia gravis, these recommendations can help patients to achieve the best therapeutic goals.